Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherChemotherapy, Antibiotics, and Gene Therapy

Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting

Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Häkkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle and Heikki Joensuu
Journal of Pharmacology and Experimental Therapeutics January 12, 2023, JPET-AR-2022-001444; DOI: https://doi.org/10.1124/jpet.122.001444
Jouko Levijoki
1Oncology Research, Orion Corporation, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jouko Levijoki
  • For correspondence: jouko.levijoki@orionpharma.com
Lasse Saloranta
2Animal Welfare & AH Microbiome, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Tuunainen
3Translational PK/PD, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janne Kaskinoro
4Antibody Drug Conjugates, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sari Pappinen
5Biopharmaceutics and Chemical Analytic, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Nourry
6Pharmacology, Biotrial, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Marie Betat
6Pharmacology, Biotrial, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Maurin
6Pharmacology, Biotrial, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarit Pakarinen
7Translational Bioanalytics & Biomarkers, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sari Häkkinen
7Translational Bioanalytics & Biomarkers, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Tervapuro
8Formulation Development and CTS, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hertta Pihlasvaara
9Structural Biology and Analytics, Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Drieu La Rochelle
6Pharmacology, Biotrial, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heikki Joensuu
10Department of Oncology, Orion Corporation Orion Pharma and Helsinki University Hospital and University of Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Cancer treatments are frequently associated with nausea and vomiting despite greatly improved preventive medication. Administration of anti-nausea agents as eye drops might provide an easy and rapid access to the systemic circulation for prevention of nausea and vomiting and for the treatment of breakthrough nausea, but the ocular administration route has rarely been evaluated. Palonosetron is a second-generation 5-HT3 receptor antagonist approved for prevention and treatment of chemotherapy-induced nausea and vomiting. We compared ocular administration of palonosetron to non-active vehicle eye drops and to intravenous palonosetron in the prevention of cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron ocular drops at the dose of 30 µg/kg reduced cumulative nausea over time as measured with the area under the visual analog scale curve (VAS-AUC) by 98% compared with the vehicle, and reduced nausea-associated dog behavior by 95%. Vomiting was completely prevented with repeated palonosetron ocular dosing. Hydroxypropyl-β-cyclodextrin (HP-β-CD) palonosetron formulation was well tolerated locally at the palonosetron concentration of 3 mg/mL. Absorption of palonosetron from eye drops was fast. Ten minutes after ocular administration, palonosetron plasma concentrations were similar compared to intravenous administration, and remained similar for six hours. We conclude that palonosetron is rapidly absorbed into the systemic circulation from eye drops. Ocularly administered palonosetron was well tolerated in the HP-β-CD formulation and was highly effective in the prevention of cisplatin-induced nausea and vomiting. Evaluation of the safety and efficacy of ocular administration of palonosetron is warranted in the prevention and treatment of chemotherapy-induced nausea and vomiting in clinical trials.

Significance Statement Palonosetron, an effective and well-tolerated antiemetic drug was rapidly absorbed into the systemic blood circulation when administered as eye drops. The achieved palonosetron blood concentrations prevented cisplatin-induced nausea and vomiting in beagle dogs. Palonosetron eye drops might provide an easy and quick method for administering palonosetron when parenteral administration is desired and intravenous administration is not feasible.

  • 5-HT receptors
  • animal/nonclinical/preclinical
  • anticancer agents
  • Anti-cancer agents
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherChemotherapy, Antibiotics, and Gene Therapy

Ocular Palonosetron for Prevention of Nausea and Vomiting

Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Häkkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle and Heikki Joensuu
Journal of Pharmacology and Experimental Therapeutics January 12, 2023, JPET-AR-2022-001444; DOI: https://doi.org/10.1124/jpet.122.001444

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherChemotherapy, Antibiotics, and Gene Therapy

Ocular Palonosetron for Prevention of Nausea and Vomiting

Jouko Levijoki, Lasse Saloranta, Johanna Tuunainen, Janne Kaskinoro, Sari Pappinen, Sandra Nourry, Anne-Marie Betat, Anne Maurin, Maarit Pakarinen, Sari Häkkinen, Johanna Tervapuro, Hertta Pihlasvaara, Christophe Drieu La Rochelle and Heikki Joensuu
Journal of Pharmacology and Experimental Therapeutics January 12, 2023, JPET-AR-2022-001444; DOI: https://doi.org/10.1124/jpet.122.001444
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • miR-9-3p and -5p Mediate Drug Resistance by Targeting TOP2β
  • PTP4A3 and ovarian cancer
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics